Linical received FDA accelerated approval for a new breast cancer treatment.

Linical is a global Contract Research Organization (CRO) for full-service drug development, with a proven record of helping biopharmaceutical companies successfully navigate the clinical development journey. Linical is headquartered in Japan with a significant presence across all major markets including North America, Europe, and Asia-Pacific. Linical provides a full spectrum of drug development services from early stage to large-scale, multinational studies. Our areas of focus include Phase I-IV studies in oncology, neurology & psychiatry, immunology & vaccine, and endocrinology & metabolic diseases. Combining strong business perspective with clinical and medical expertise, our team goes beyond operational excellence providing flexibility, guidance, and key strategies to successfully overcome drug development and regulatory challenges. We strive to offer professional, high-quality services with the personal attention needed in a constantly evolving pharmaceutical and biotech market. Rather than be all things to the market, this intentional design allows us to provide our clients the right size, right reach, and right team.

Founded 2005